Mitralign reports the 1st-in-human use of its minimally invasive device to treat tricuspid valve regurgitation under a compassionate use allowance in Germany.
Mitralign said today that surgeons in Germany implanted its tricuspid valve repair device in its 1st patient, under a "compassionate use" allowance in Germany.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1rz0ETP
Cap comentari:
Publica un comentari a l'entrada